Skip to content

Study · Case report or series · n = 1 · 2025

3 results

Severe Hypomagnesemia and Hypocalcemia Linked to Semaglutide in Type 2 Diabetes: A Case Report.

Davis TME

The American journal of case reports6 Jan 2025Cited by 4 (Europe PMC)

PMID39757501 (opens in a new tab)PMCIDPMC11717150 (opens in a new tab)DOI10.12659/ajcr.946539 (opens in a new tab)PepBankPUB-39757501
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study3

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanCase report or seriesSafety outcome

    A 73-year-old woman with type 2 diabetes stopped low-dose subcutaneous semaglutide because of nausea and vomiting; gastrointestinal effects had largely resolved after stopping.

    In plain wordsOne woman stopped low-dose semaglutide because of nausea and vomiting, which mostly cleared after she stopped.

    Peptide
    Semaglutide
    Outcome
    Not applicableNausea and vomiting leading to semaglutide discontinuation
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    0.25 mg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    due to nausea and vomiting.
    2 context sentences
    Summary · context
    She had discontinued low-dose semaglutide (0.25 mg subcutaneous weekly) 2 weeks beforehand, and her gastrointestinal adverse effects had largely resolved.
    Summary · context
    CASE REPORT A 73-year-old woman with type 2 diabetes treated with several oral medications known to reduce serum magnesium (metformin, gliclazide, sitagliptin, esomeprazole) presented after an unwitnessed collapse at home without premonitory symptoms.

Studies that did not test the peptide alone2

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

  1. 02HumanNot a test of Semaglutide aloneCase report or seriesSafety outcome

    In a 73-year-old woman with type 2 diabetes on several drugs including semaglutide, severe hypomagnesemia was attributed to polypharmacy, with a likely contribution from recent semaglutide use.

    In plain wordsIn one woman taking many drugs, very low magnesium was linked mainly to the drug mix, with semaglutide as a likely partial contributor.

    Peptide
    Semaglutide
    Outcome
    Not applicableSevere hypomagnesemia
    Study

    n = 1

    Outcome group
    Adverse events · Metabolic and weight

    Measurements

    Serum magnesium
    < 0.3 mmol/L
    at presentation

    Source sentences

    Summary
    She was found to have an undetectable serum magnesium (<0.3 mmol/L) and hypocalcemia.
    2 context sentences
    Summary · context
    Her clinical features and course suggested she had chronic unrecognized hypomagnesemia associated with polypharmacy that progressed to a clinically severe level, with a likely contribution from recent antecedent semaglutide use.
    Summary · context
    CASE REPORT A 73-year-old woman with type 2 diabetes treated with several oral medications known to reduce serum magnesium (metformin, gliclazide, sitagliptin, esomeprazole) presented after an unwitnessed collapse at home without premonitory symptoms.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 03HumanNot a test of Semaglutide aloneCase report or seriesSafety outcome

    The same woman with type 2 diabetes on several drugs including semaglutide also had hypocalcemia at presentation.

    In plain wordsThe same woman, who took many drugs including semaglutide, also had low calcium.

    Peptide
    Semaglutide
    Outcome
    Not applicableHypocalcemia
    Study

    n = 1

    Outcome group
    Adverse events · Metabolic and weight

    Source sentences

    Summary
    She was found to have an undetectable serum magnesium (<0.3 mmol/L) and hypocalcemia.
    1 context sentence
    Summary · context
    CASE REPORT A 73-year-old woman with type 2 diabetes treated with several oral medications known to reduce serum magnesium (metformin, gliclazide, sitagliptin, esomeprazole) presented after an unwitnessed collapse at home without premonitory symptoms.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.